Topic: Personalized medicine
Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
The hyperpersonalization trend means pharmarketers are going to use advanced data and analytics to target audiences as small as one.
Kite's new CAR-T approval vaults it and new parent Gilead into a market first launched by Novartis—and into the debate over high drug prices.
One cancer patient is urging Novartis to weigh taxpayer investment in early-stage CAR-T science in setting a price on its new med tisagenlecleucel.
The highly valued yet mysterious Moderna provided a peek at its first human data, reporting positive interim results from a phase 1 trial testing its mRNA-based H10N8 flu vaccine.